Department of Nephrology, Université Paris Descartes, Hôpital Necker, Paris, France.
Clin J Am Soc Nephrol. 2010 Feb;5(2):205-10. doi: 10.2215/CJN.06610909. Epub 2010 Jan 14.
Kidney biopsy (KB), to date the only tool for the evaluation of renal fibrosis, carries specific risks, and its relevance is limited by the small size of renal parenchyma assessed. Thus, a noninvasive alternative to KB is required. Collagen type III amino-terminal propeptide (PIIINP) is a degradation product of collagen type III, the increase of which may reflect an ongoing fibrotic process.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a prospective study including 199 patients with various stages of chronic kidney disease (CKD), the association between urinary PIIINP/creatinine ratio (UPIIINP/Cr), patients' characteristics, and renal fibrosis was assessed.
A total of 118 of the patients had UPIIINP/Cr measured simultaneously with the performance of a KB. In patients, median UPIIINP/Cr was 290 ng/mmol versus 93.7 ng/mmol in controls. In univariate analysis, UPIIINP/Cr was correlated with serum creatinine, estimated GFR, CKD stage, presence of coronary artery disease, and nephropathy type (glomerulonephritis versus other types). In multivariate analysis, only estimated GFR and nephropathy type were correlated with UPIIINP/Cr. UPIIINP/Cr was closely correlated with the extent of interstitial fibrosis in KB assessed using two different methods. Moreover, UPIIINP/Cr >800 ng/mmol had a negative predictive value of 94% to detect patients in whom KB will eventually prove "noninformative" (KB leading neither to a definite diagnosis of nephropathy nor to specific treatment).
UPIIINP/Cr is a promising fibro-test for the kidney and may alleviate the need for KB in some patients with CKD. Its predictive value for CKD progression deserves evaluation in prospective studies.
肾脏活检(KB)是目前评估肾纤维化的唯一工具,具有特定的风险,并且其相关性受到评估的肾实质体积小的限制。因此,需要一种非侵入性的替代 KB 的方法。III 型胶原氨基末端前肽(PIIINP)是 III 型胶原的降解产物,其增加可能反映了持续的纤维化过程。
设计、设置、参与者和测量:在一项包括 199 名患有各种慢性肾脏病(CKD)阶段的患者的前瞻性研究中,评估了尿 PIIINP/肌酐比(UPIIINP/Cr)与患者特征和肾纤维化之间的关系。
共有 118 名患者同时进行了 UPIIINP/Cr 测量和 KB 检查。在患者中,中位数 UPIIINP/Cr 为 290ng/mmol,而对照组为 93.7ng/mmol。在单因素分析中,UPIIINP/Cr 与血清肌酐、估计肾小球滤过率(eGFR)、CKD 分期、冠心病和肾病类型(肾小球肾炎与其他类型)相关。在多因素分析中,仅 eGFR 和肾病类型与 UPIIINP/Cr 相关。UPIIINP/Cr 与使用两种不同方法评估的 KB 中间质纤维化的程度密切相关。此外,UPIIINP/Cr>800ng/mmol 对检测 KB 最终将证明“无信息”(KB 既不能确定肾病的诊断,也不能进行特定治疗)的患者具有 94%的阴性预测值。
UPIIINP/Cr 是一种有前途的肾脏纤维化检测方法,可能减轻一些 CKD 患者对 KB 的需求。其对 CKD 进展的预测价值值得在前瞻性研究中评估。